Akebia Therapeutics, Inc. (AKBA) stock

AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30

$0.47−0.02 (-4.78%)

Close on Nov 13, 2026Market cap $131.40MP/E –Yield –

Akebia Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Akebia Therapeutics's EV/EBITDA was 45.4× on Jul 31, 2026.

Period	Period end	Value	Change (pts)
2026	Jul 31, 2026	45.4×	+28.1
2025	Dec 31, 2025	17.3×	–

Parsed from the XBRL in Akebia Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is AKBA.

Revenue growth-12.4% · median 21.0%

Gross margin78.9% · median 93.8%

Operating margin-15.7% · median -18.2%

Net margin-22.6% · median -12.4%

Advertisement
300 × 250

See a number that looks wrong?